Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women
American Journal of Hematology · 2025-07 · 100 (7) · 1132-1140
DOI: 10.1002/ajh.27686 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 16.04.2025. Verfasst von Daniel Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Ferritins, Mass Screening, Anemia, Iron-Deficiency, Iron Deficiencies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Iron deficiency (ID) is a top five leading cause of disability‐adjusted life‐years in women of reproductive age around the world. Despite its enormous health burden, no screening guidelines exist for the detection and treatment of ID in women of reproductive age. We sought to determine the cost‐effectiveness of screening versus no screening for ID in women of reproductive age in the United States. A lifetime simulation of women of reproductive age was conducted using a Markov cohort model under three strategies: (1) no screening, (2) screening at a ferritin threshold of 15 μg/L, and (3) screening at a ferritin threshold of 25 μg/L, from the US health system perspective, and at a willingness‐to‐pay threshold of $100 000/quality‐adjusted life year (QALY). Epidemiologically informed ID prevalence estimates sourced from the National Health and Nutrition Examination Survey were employed for model parameterization. The primary outcome was the incremental cost‐effectiveness ratio (ICER, in $/QALY). Base‐case results for the three strategies accrued $209 700, $210 200, and $210 200 discounted lifetime costs and 23.6, 24.0, and 24.4 discounted lifetime QALYs, respectively. Screening at a ferritin threshold of 25 μg/L was the cost‐effective intervention with an ICER of $680/QALY (95% credible interval $350–$750/QALY). In dual base‐case analyses examining intravenous rather than oral iron repletion for treatment, screening at a ferritin threshold of 25 μg/L remained the cost‐effective intervention with an ICER of $2300/QALY (95% CI $1800–$3800/QALY). In probabilistic sensitivity analyses, screening at a ferritin threshold of 25 μg/L was the cost‐effective intervention in 100% of 10 000 second order Monte Carlo iterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, Connecticut, USA.
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Yale College, New Haven, Connecticut, USA.
- University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
- Section of Medical Oncology & Hematology, Yale University School of Medicine & Yale Cancer Center, New Haven, Connecticut, USA.
- Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: George Goshua
Förderung
- NHLBI NIH HHS
Zitieren
APA
Wang, D., Sra, M., Glaeser-Khan, S., Wang, D. Y., Moshashaian-Asl, R., Ito, S., Cuker, A., & Goshua, G. (2025). Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women. American Journal of Hematology, 100(7), 1132-1140. https://doi.org/10.1002/ajh.27686
Vancouver
Wang D, Sra M, Glaeser-Khan S, Wang DY, Moshashaian-Asl R, Ito S, et al. Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women. American Journal of Hematology. 2025;100(7):1132-1140. doi:10.1002/ajh.27686
BibTeX
@article{Wang2025,
author = {Wang, Daniel and Sra, Manraj and Glaeser-Khan, Samira and Wang, Daniel Y and Moshashaian-Asl, Ranya and Ito, Satoko and Cuker, Adam and Goshua, George},
title = {Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {7},
pages = {1132--1140},
doi = {10.1002/ajh.27686}
}
EUVIMED